14.73
price down icon8.85%   -1.43
after-market Handel nachbörslich: 13.50 -1.23 -8.35%
loading
Schlusskurs vom Vortag:
$16.16
Offen:
$15.6
24-Stunden-Volumen:
2.14M
Relative Volume:
0.93
Marktkapitalisierung:
$1.75B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-3.7577
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
-6.36%
1M Leistung:
+9.93%
6M Leistung:
+47.01%
1J Leistung:
+37.02%
1-Tages-Spanne:
Value
$14.26
$16.04
1-Wochen-Bereich:
Value
$14.26
$17.43
52-Wochen-Spanne:
Value
$6.99
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Firmenname
Arcutis Biotherapeutics Inc
Name
Telefon
805-418-5006
Name
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Mitarbeiter
342
Name
Twitter
@ArcutisBio
Name
Nächster Verdiensttermin
2024-12-06
Name
Neueste SEC-Einreichungen
Name
ARQT's Discussions on Twitter

Vergleichen Sie ARQT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
14.73 1.75B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-30 Eingeleitet H.C. Wainwright Buy
2024-08-28 Eingeleitet Jefferies Buy
2024-01-03 Hochstufung Mizuho Neutral → Buy
2023-10-26 Herabstufung Mizuho Buy → Neutral
2023-10-13 Herabstufung Goldman Buy → Neutral
2022-09-07 Eingeleitet Needham Buy
2022-03-17 Eingeleitet Goldman Buy
2021-06-30 Eingeleitet Mizuho Buy
2021-05-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-11-09 Hochstufung Goldman Neutral → Buy
2020-10-08 Eingeleitet Truist Buy
2020-02-25 Eingeleitet Cantor Fitzgerald Overweight
2020-02-25 Eingeleitet Cowen Outperform
2020-02-25 Eingeleitet Goldman Neutral
2020-02-25 Eingeleitet Guggenheim Buy
Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

pulisher
04:17 AM

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

04:17 AM
pulisher
04:00 AM

Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan

04:00 AM
pulisher
11:00 AM

(ARQT) Trading Report - news.stocktradersdaily.com

11:00 AM
pulisher
Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Recent Insider Transactions at Arcutis Biotherapeutics - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance

Apr 03, 2025
pulisher
Apr 03, 2025

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Apr 03, 2025
pulisher
Apr 02, 2025

Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis rises after halting patent dispute with Padagis - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine

Apr 02, 2025
pulisher
Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025
pulisher
Mar 31, 2025

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN

Mar 30, 2025
pulisher
Mar 28, 2025

Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 27, 2025
pulisher
Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st

Mar 26, 2025
pulisher
Mar 25, 2025

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Mar 25, 2025
pulisher
Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zorvye foam - Medical Marketing and Media

Mar 24, 2025
pulisher
Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - MM+M Online

Mar 24, 2025
pulisher
Mar 20, 2025

Arcutis Biotherapeutics shares jump - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India

Mar 20, 2025
pulisher
Mar 17, 2025

What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow

Mar 17, 2025
pulisher
Mar 17, 2025

Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail

Mar 17, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa

Mar 11, 2025

Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):